Association between the CYP2C9 polymorphism and the drug metabolism phenotype
-
Elizabeta Topic
Abstract
CYP2C9, an isoform of the cytochrome P450 enzyme, is involved in the metabolism of most of the drugs of choice for the treatment of thromboembolic disorders. Functional polymorphism is associated with two variant alleles (alleles *2 and *3) encoding CYP2C9 enzymes with a potentially different catalytic activity. The aim of the study was to determine the frequency of the CYP2C9 polymorphism in a representative sample of the Croatian population (n=177) and to assess the association between the CYP2C9 polymorphism and the warfarin dose in patients with thromboembolism (n=181). The CYP2C9 genotype was determined by polymerase chain reaction-restriction fragment length poymorphism (PCR-RFLP). According to the CYP2C9 genotype distribution, 31.2% of the healthy subjects were identified with a heterozygous or homozygous CYP2C9 variant genotype. The frequency of 2C9*2 and 2C9*3 alleles was 12.4% and 3.7%, respectively. There was no gender-related genotype or allele difference. In thromboembolism patients, the frequency of CYP2C9 alleles *2 and *3 was 17.4% and 6.6%, respectively, and did not differ significantly from the control group. Almost half (42.5%) of the patients carried at least one variant CYP2C9 genotype. The allele difference between patient subgroups receiving warfarin doses lower and higher than the optimal warfarin dose (4.1 mg/day) was significant (p=0.027), especially for allele 2C9*3 (p=0.019; OR 3.250, 95%, CI 1.263–8.413). Comparison of the warfarin dose between patients with different genotypes yielded a significant dose difference between the patients with wild-type genotype and those with variant genotypes (Kruskall-Wallis, χ2=9.745, p=0.008). The results of the association of each of five genotype combinations with the warfarin maintenance dose revealed it to be significantly related to the genotype (Kruskall-Wallis, χ2=12.854, p=0.025). Expressed as percentage of the mean dose in patients with wild-type alleles, the mean warfarin maintenance dose was 92% in 2C9*2 heterozygotes, 74% in 2C*3 heterozygotes, 61% in 2C9*2 homozygotes, 34% in 2C9*3 homozygotes and 63% in compound heterozygotes for 2C9*2 and 2C9*3. Although the mean maintenance dose in homozygous *2/*2 and compound *2/*3 genotype patients was markedly lower (mean 2.66 mg and 2.75 mg, respectively, vs. 4.37 mg), statistical analysis yielded no significance because of the small number of patients carrying these genotypes. A significantly lower maintenance dose was observed in the subgroup of heterozygous *1/*3 genotype patients (p=0.022). These preliminary results suggest a significant association of the CYP2C9 polymorphism with the warfarin dose and underline the importance of pre-therapeutic genotyping to identify the subjects likely to develop undesirable drug effects.
Copyright © 2004 by Walter de Gruyter GmbH & Co. KG
Articles in the same Issue
- International collaboration in clinical chemistry and laboratory medicine: the Human Proteome Organization (HUPO) Plasma Proteome Project
- Current concepts in standardization of cardiac marker immunoassays
- Collagen, ageing and nutrition
- Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction
- High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy
- Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience
- Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B
- Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide
- Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine
- Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples
- Blood alcohol testing: comparison of the performance obtained with the different methods used in the Belgian external quality assessment schemes
- Determination of lipase catalytic activity in two reference materials: BCR 693 and BCR 694 by titrimetry at constant pH
- Evaluation of a new generation of plastic evacuated blood-collection tubes in clinical chemistry, therapeutic drug monitoring, hormone and trace metal analysis
- Association between the CYP2C9 polymorphism and the drug metabolism phenotype
- Analytical goals for coagulation tests based on biological variation
- In vivo total antioxidant capacity: comparison of two different analytical methods
- Performance evaluation of automated assays for β-CrossLaps, N-MID-Osteocalcin and intact parathyroidhormone (BIOROSE Multicenter Study)
- Evaluation of the blood gas analyzer GEM(r) PREMIER(tm) 3000
- Lactate dehydrogenase (LD) extra isoenzyme electrophoretic band between LD1 and LD2 caused by a complex with α1-lipoprotein. A case report
- Relationship between cryoglobulins and hepatitis C virus (HCV) core antigen or antibody titers
- Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter
- Biological variation of plasma chromogranin A
- Verification, validation and evaluation of analytical procedures in laboratory medicine
- DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus Paper on the Rational Clinical Use of Homocysteine, Folic Acid and B-Vitamins in Cardiovascular and Thrombotic Diseases: Guidelines and Recommendations
- Meetings and Awards
Articles in the same Issue
- International collaboration in clinical chemistry and laboratory medicine: the Human Proteome Organization (HUPO) Plasma Proteome Project
- Current concepts in standardization of cardiac marker immunoassays
- Collagen, ageing and nutrition
- Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction
- High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy
- Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience
- Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B
- Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide
- Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine
- Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples
- Blood alcohol testing: comparison of the performance obtained with the different methods used in the Belgian external quality assessment schemes
- Determination of lipase catalytic activity in two reference materials: BCR 693 and BCR 694 by titrimetry at constant pH
- Evaluation of a new generation of plastic evacuated blood-collection tubes in clinical chemistry, therapeutic drug monitoring, hormone and trace metal analysis
- Association between the CYP2C9 polymorphism and the drug metabolism phenotype
- Analytical goals for coagulation tests based on biological variation
- In vivo total antioxidant capacity: comparison of two different analytical methods
- Performance evaluation of automated assays for β-CrossLaps, N-MID-Osteocalcin and intact parathyroidhormone (BIOROSE Multicenter Study)
- Evaluation of the blood gas analyzer GEM(r) PREMIER(tm) 3000
- Lactate dehydrogenase (LD) extra isoenzyme electrophoretic band between LD1 and LD2 caused by a complex with α1-lipoprotein. A case report
- Relationship between cryoglobulins and hepatitis C virus (HCV) core antigen or antibody titers
- Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter
- Biological variation of plasma chromogranin A
- Verification, validation and evaluation of analytical procedures in laboratory medicine
- DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus Paper on the Rational Clinical Use of Homocysteine, Folic Acid and B-Vitamins in Cardiovascular and Thrombotic Diseases: Guidelines and Recommendations
- Meetings and Awards
